Dr. Pahwa discusses the use of continuous subcutaneous Vyalev (foscarbidopa/foslevodopa) infusion to address motor fluctuations and nighttime symptoms in patients with Parkinson’s disease. Clinical trial findings showed increased good “on” time compared with oral carbidopa/levodopa, while post-hoc analyses using the Parkinson’s Disease Sleep Scale (PDSS) demonstrated improvements in motor symptoms, Parkinson’s disease symptoms, and general sleep disturbances. Dr. Pahwa explains how continuous infusion could help extend symptom control through the night and into the early morning, supporting a more comprehensive approach to 24-hour Parkinson’s disease management. The discussion also addresses individualized nighttime dosing, including dose reduction when adverse effects occur.
Topics Covered:
- Management of motor fluctuations with continuous subcutaneous levodopa infusion
- PDSS-2 outcomes across motor symptoms at night, Parkinson’s disease symptoms at night, and disturbed sleep
- Individualized daytime and nighttime dosing for 24-hour symptom control
